ESTRO 38 Abstract book

S127 ESTRO 38

307 lung metastases in 209 patients were treated with SBRT between 2002 and 2017. All patients were enclosed into our retrospective study and documented in the research database of the department of radiation oncology. We documented side effects according to the CTCAE criteria (v.4.03). Patients, that were still alive and had no follow-up visit for more than six months in our department, received an invitation to our patient survey via mail. The questionnaire contained 13 questions of PRO- CTCAE™ (developed by the NCI) and two self-created questions regarding their state of health and wellbeing. Patients were able to participate using our web-based survey system or if preferred paper-based. Results Patients Median overall survival (OS) was 19 months (interquartile range (IQR) 7.8 to 41.3 months), median progression-free survival (PFS) was 6.4 months (IQR 2.2 to 16.9 months). The median local control (LC) was 11.6 months (IQR 4.6 to 27.6 months). The pulmonary lesions were treated with a median dose of 35 Gy to the 60% isodose. The Karnofsky Performance Score approved as a statistically significant impact on OS (p<0.001) and PFS (p=0.018).

Toxicity The documented side-effects were mainly graded 1 or 2 (Table 1). Doctors only recorded severe side-effects (grade 3 or 4) in six participant’s cases.

Conclusion Overall, scores worsened after RT in different HRQoL domains, but pts did not perceive a global change in their HRQoL status. The Spanish version of the EPIC-16 questionnaire demonstrated sensitivity to detect PCa treatment-related effects and sensitivity for clinical improvement after RT. It also showed strong discriminative properties and reliability, demonstrating its validity for use in clinical practice and clinical trials to evaluate the effect of interventions. PV-0258 Patient reported outcome and survival analysis after stereotactic body RT (SBRT) of lung metastases R. Grosser 1 , K.A. Kessel 1,2 , D. Marciana-Nona 2,3 , M. Oechsner 1 , S.E. Combs 1,2 1 Klinikum rechts der Isar- Technical University of Munich, Radiation Oncology, Munich, Germany; 2 Institute of Innovative Radiotherapy, Institute of Innovative Radiotherapy, Munich, Germany; 3 Klinikum rechts der Isar - Technical University of Munich, Radiation Oncology, Munich, Germany Purpose or Objective Stereotactic body radiation therapy (SBRT) is a high- precision method to irradiate extracranial targets. In this evaluation, we analyzed patients that underwent SBRT of pulmonary metastases. We focused on toxicity and the efficiency of SBRT in order to gain a long-term patient reported outcome (PRO). Material and Methods

PRO assessment Out of living 40 patients, 36 (90%) participated in our survey; four patients told us only the status of their actual disease which was stable. The median time between radiation therapy (RT) and PRO was 46.8 months (IQR 16.9 to 93.1). Patients noted radiodermatitis grade 3 (n=1), sensory disorders grade 4 (n=1) and 3 (n=2), motor disorders grade 3 (n=2), dysphagia grade 3 (n=1), dyspnea grade 3 (n=2) and 4 (n=2) and cough grade 3 (n=1). All patients with severe dyspnea were diagnosed a COPD before SBRT. During PRO assessment, one patient noted four and another patient three grade 3 adverse effects. It appears that subjective personal sensitivity has a relevant influence on how patients filled out the questionnaire. Conclusion Our results showed low levels of acute, late, long and PRO toxicities. Hence, SBRT is a suitable treatment method for patients with lung metastases, who are unwilling to undergo surgery, or patients, who are functionally